DMKPQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DMKPQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, DMK Pharmaceuticals's Enterprise Value is $0.02 Mil. DMK Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-17.36 Mil. Therefore, DMK Pharmaceuticals's EV-to-EBIT for today is -0.00.
The historical rank and industry rank for DMK Pharmaceuticals's EV-to-EBIT or its related term are showing as below:
During the past 13 years, the highest EV-to-EBIT of DMK Pharmaceuticals was 0.37. The lowest was -6.75. And the median was -2.06.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. DMK Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was $0.29 Mil. DMK Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-17.36 Mil. DMK Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -5,960.24%.
The historical data trend for DMK Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's EV-to-EBIT falls into.
DMK Pharmaceuticals's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 0.022 | / | -17.355 | |
= | -0.00 |
DMK Pharmaceuticals's current Enterprise Value is $0.02 Mil.
DMK Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals (OTCPK:DMKPQ) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
DMK Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) | = | EBIT | / | Enterprise Value (Q: Sep. 2023 ) |
= | -17.355 | / | 0.2911794 | |
= | -5,960.24 % |
DMK Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was $0.29 Mil.
DMK Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of DMK Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Dorbin John W. Jr. | officer: General Counsel | C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402 |
Seth Cohen | officer: CFO | C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018 |
Ebrahim Versi | director, officer: CEO | 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Jannine Versi | director | 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Vickie S Reed | director | TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037 |
David J. Marguglio | director | 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014 |
Carlo Dennis J Phd | director, 10 percent owner, officer: President/CEO | PO BOX 1176, RANCHO SANTA FE CA 92067 |
Ronald B. Moss | officer: Chief Medical Officer | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
David C. Benedicto | officer: Chief Financial Officer | 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Meera J. Desai | director | 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130 |
Robert O Hopkins | officer: Chief Financial Officer | 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014 |
Karen K. Daniels | officer: Vice President of Operations | 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130 |
Howard C Birndorf | director | C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Roshawn A. Blunt | director | 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130 |
Richard C Williams | director | 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134 |
From GuruFocus
By PRNewswire • 08-02-2023
By Marketwired • 10-19-2023
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By PRNewswire • 06-26-2023
By GuruFocus Research • 02-06-2024
By PRNewswire • 08-03-2023
By Marketwired • 08-04-2023
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.